Drug Profile
Research programme: CYP17A inhibitors - Beta Pharma
Alternative Names: BPI-5143Latest Information Update: 25 Jul 2023
Price :
$50
*
At a glance
- Originator Beta Pharma
- Class
- Mechanism of Action CYP17A1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 25 Jul 2023 As at July 2023, CYP17A inhibitors was no longer listed on the company pipeline and NDR status for preclinical studies is from more than 4 years hence discontinued profile
- 25 Jul 2023 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Prostate-cancer in USA